<DOC>
	<DOC>NCT02658747</DOC>
	<brief_summary>This is a multi-center retrospective observational research study collecting data for participants initiated on docetaxel for the treatment of relapsed non-small cell lung cancer (NSCLC) up to 6 years before start of data collection and who have completed/stopped docetaxel treatment at least 30 days prior to data collection. The primary goal of this study is to describe the percentage of participants with at least one neutropenic sepsis (NS) episode following initiation of treatment with single-agent docetaxel. Data will be collected until end of docetaxel treatment plus an additional 30 days to allow for presentation with toxicity.</brief_summary>
	<brief_title>Neutropenic Sepsis in Patients With Non-Small Cell Lung Cancer Treated With Single-Agent Docetaxel and Associated Resource Use in the UK</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Diagnosed with locally advanced or metastatic (stage Ill or IV) nonsmall cell lung cancer (NSCLC) Relapsed disease following, or unable to tolerate, at least one line of prior chemotherapy Initiated on singleagent docetaxel up to a maximum of 6 years prior to date of collection Aged 18 years at date of first docetaxel dose Completed or stopped treatment with docetaxel at least 30 days prior to date of data collection Receiving docetaxel in an interventional clinical trial For whom no details of absolute neutrophil count are recorded</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>